This Viewpoint describes reforms to the ways the National Health Service (NHS) appraises cost-effectiveness and coverage of cancer drugs in England and Wales, the role of the National Institute for Health and Care Excellence (NICE) in the process, and changes in drug approval rates and access to new drugs as a result.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2BIhWGd
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Assessment of water quality status of a river with respect to its discharge has become prerequisite to sustainable river basin man...
-
Viruses, Vol. 10, Pages 61: Virus–Bacteria Interactions: Implications and Potential for the Applied and Agricultural Sciences Viruses doi: ...
-
by Alison M. Hixon, Guixia Yu, J. Smith Leser, Shigeo Yagi, Penny Clarke, Charles Y. Chiu, Kenneth L. Tyler In 2014, the United States exp...
-
Related Articles Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque p...
-
Accumulating data have indicated that citrus polymethoxyflavones (PMFs) have the ability to affect brain function. In the present study, we ...
-
No large-scale, head-to-head, phase III, randomized, controlled trial with an adequate sample size has investigated the effect of concurrent...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου